Syndax Pharmaceuticals Inc. has announced the granting of inducement awards as part of its 2023 Inducement Plan. Effective July 1, 2025, the company has provided stock options to purchase up to 228,400 shares of common stock to 14 new employees. These options will vest over a period of four years, with an initial 25% of the shares vesting on the first anniversary of the vesting commencement date. Thereafter, 1/48th of the shares will vest monthly over the following 36 months, contingent on the employees' continued service with the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.